Chicago (PRWEB) May 18, 2018
The top research abstracts submitted to the American Society of Gene & Cell Therapy's 21st Annual Meeting, May 16-19 at the Hilton Chicago, are presented today as part of the Presidential Symposium & Presentation of the Top Abstracts at 1:15 p.m. in the Hilton Chicago's International Ballroom.
Prior to the abstract presentations, CAR T-cell therapy pioneer Nicholas Restifo, MD, senior investigator at the National Cancer Institute, delivers a lecture to the entirety of the annual meeting. Following Dr. Restifo's talk, the following abstracts will be presented:
- Translating RNAi for Huntington’s Disease: Intra-Putaminal Delivery of AAV2/1.Mihds1 for Comprehensive Dosing, Biodistribution, Silencing and Safety in a Non-Human Primate
- In Utero Gene Correction Mediated by PNA-Nanoparticles
- Engraftment and Phenotypic Correction of Hematopoietic Stem Cells in Non-Conditioned Fanconi Anemia Patients Treated with Ex Vivo Gene Therapy
- Transplantation and Persistence of CRISPR/Cas9 -Edited Hematopoietic Stem and Progenitors Cells for the Reactivation of Fetal Hemoglobin in Nonhuman Primates
For more information or to schedule the opportunity to speak with one or more of the authors of these abstracts, contact ASGCT Digital Communications Manager Alex Wendland.
About The American Society of Gene & Cell Therapy
ASGCT is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. The Society’s mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease. ASGCT’s vision is to serve as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society.